Pyrazinamide monoresistance in clinical isolates

Authors

NEZAKET KALIR
AYŞE AYDAN ÖZKÜTÜK
NURAN ESEN
NURİ ÖZKÜTÜK

DOI

10.3906/sag-1204-40

Abstract

To determine pyrazinamide (PZA) monoresistance in clinical isolates of Mycobacterium tuberculosis complex (MTBC) isolated in hospitals in and around İzmir. Materials and methods: The study was performed between 2004 and 2009 with 150 streptomycin, isoniazid, rifampicin, and ethambutol susceptible MTBC clinical strains isolated in the university hospitals of İzmir and Manisa. The PZA susceptibility of the isolates was determined by the BACTEC 460 TB test. Results: The results indicated that resistance to PZA was present in 5 (3.3%) of the 150 MTBC isolates susceptible to all primary drugs except PZA. Conclusion: It is not essential to perform PZA susceptibility tests routinely along with other primary drugs due to the low PZA monoresistance level in our region.

Keywords

Mycobacterium tuberculosis, antituberculosis susceptibility test, pyrazinamide resistance, BACTEC 460TB

First Page

163

Last Page

167

Recommended Citation

KALIR, NEZAKET; ÖZKÜTÜK, AYŞE AYDAN; ESEN, NURAN; and ÖZKÜTÜK, NURİ (2013) "Pyrazinamide monoresistance in clinical isolates," Turkish Journal of Medical Sciences: Vol. 43: No. 1, Article 28. https://doi.org/10.3906/sag-1204-40
Available at: https://journals.tubitak.gov.tr/medical/vol43/iss1/28